00:43 , Jun 22, 2019 |  BC Extra  |  Financial News

WuXi stocks tumble as Rubio continues to press China agenda

WuXi Biologics and WuXi AppTec ended down about 6% in Hong Kong on Friday, losing a combined $765 million in market cap, as Sen. Marco Rubio (R-Fla.) continued to ratchet up pressure on China's life...
11:31 , Jun 10, 2019 |  BioCentury  |  Finance

$80M series B backs Oncologie's biomarkers, which could give new life to old therapies

Oncologie's strategy of pairing in-licensed, later-stage compounds with biomarkers led Nan Fung Life Sciences and Pivotal bioVenture Partners China to return to invest in the cancer company's tranched $80 million series B. The funds are...
04:00 , Jun 5, 2019 |  BioCentury  |  Finance

EpimAb raises $74M series B round to accelerate bispecific immuno-oncology pipeline expansion

With proof in hand that EpimAb can quickly move bispecific mAbs from concept to the clinic, the Shanghai company intends to use its $74 million series B round to rapidly expand its pipeline of bispecific...
00:29 , May 25, 2019 |  BC Extra  |  Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise...
22:28 , May 6, 2019 |  BC Extra  |  Company News

Management tracks: Batu, Halozyme, FOG

Immunotherapy company Batu Biologics Inc. , (San Diego, Calif.) said founder Thomas Ichim has become president and CEO. Ichim, also a director, was previously Batu's CSO. He succeeds founder Samuel Wagner, who stepped down and...
00:01 , Apr 30, 2019 |  BioCentury  |  Finance

Why liver disease newco Alentis is aiming for one of largest Swiss A rounds

Liver disease newco Alentis Therapeutics is starting off small with the first close of its series A round, but the additional capital it expects to raise over the next six months could give it the...
14:31 , Apr 26, 2019 |  BC Extra  |  Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
00:41 , Apr 6, 2019 |  BC Extra  |  Politics & Policy

CFIUS drawing line in sand on personal data

The Trump administration has further reinforced which kinds of life science investments will be off limits for foreign investors, as reports emerge that CFIUS is compelling two more Chinese firms to relinquish control over companies...
22:55 , Feb 22, 2019 |  BioCentury  |  Finance

MPM keeps building

MPM Capital’s new $400 million BioVentures 2018 fund will complement the firm’s cancer-focused initiatives and enable it to continue its company building strategy. BioVentures 2018 closed on Feb. 21 and follows in the footsteps of...
19:08 , Feb 22, 2019 |  BC Week In Review  |  Financial News

MPM closes $400M BioVentures 2018 fund

MPM Capital closed BioVentures 2018 at $400 million to fund early stage biotechs. BioVentures 2018, the firm's seventh fund, will invest in therapeutic areas including oncology, immunology and neuroscience, as well as in modalities such...